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Abstract
 
p62
 
dok
 
 has been identified as a substrate of many oncogenic tyrosine kinases such as the chronic
myelogenous leukemia (CML) chimeric p210
 
bcr-abl
 
 oncoprotein. It is also phosphorylated upon
activation of many receptors and cytoplamic tyrosine kinases. However, the biological func-
tions of p62
 
dok
 
 in normal cell signaling as well as in p210
 
bcr-abl
 
 leukemogenesis are as yet not
fully understood. Here we show, in hemopoietic and nonhemopoietic cells derived from
 
p62
 
dok
 

 
/
 

 
 mice, that the loss of 
 
p62
 
dok
 
 results in increased cell proliferation upon growth factor
treatment. Moreover, Ras and mitogen-activated protein kinase (MAPK) activation is mark-
edly sustained in 
 
p62
 
dok
 

 
/
 

 
 cells after the removal of growth factor. However, 
 
p62
 
dok
 
 inactiva-
tion does not affect DNA damage and growth factor deprivation–induced apoptosis. Further-
more, 
 
p62
 
dok
 
 inactivation causes a significant shortening in the latency of the fatal
myeloproliferative disease induced by retroviral-mediated transduction of p210
 
bcr-abl
 
 in bone
marrow cells. These data indicate that p62
 
dok
 
 acts as a negative regulator of growth factor–
induced cell proliferation, at least in part through downregulating Ras/MAPK signaling path-
way, and that p62
 
dok
 
 can oppose leukemogenesis by p210
 
bcr-abl
 
.
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Introduction
 
Chronic myelogenous leukemia (CML)
 
*
 
 is a clonal disor-
der of the hematopoietic cells characterized by the presence
of the Philadelphia chromosome (Ph
 

 
), which is the result
of a chromosomal translocation between the BCR gene on
chromosome 22 and the ABL gene on chromosome 9 (1).
A chimeric protein known as bcr-abl originates from this
translocation, and its p210 form is the causative mutation
found in 95% of cases of CML. p210
 
bcr-abl
 
 has heightened
tyrosine kinase activity and exists exclusively in cytoplasm
compared with endogenous c-ABL (2). Over an average
span of 3 to 5 yr termed as chronic phase of CML, during
which the Ph
 

 
 cells populate the entire intermediate and
late hematopoietic maturational compartments, the disease
progresses leading unavoidably to an acute malignant stage
known as blast crisis. The affected cells acquire additional
genetic changes, and lose their ability to differentiate and
mature, resulting in the functional breakdown of the he-
matopoietic system (3).
 
p62
 
dok
 
 
 
was cloned as a major phosphorylation substrate of
the p210
 
bcr-abl
 
 oncoprotein in Ph
 
 
 
CML blasts (4), as well as
a target of v-Abl kinase activity in v-Abl–transformed B
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Abbreviations used in this paper: 
 
BMMC, bone marrow–derived mast
cell; CML, chronic myelogenous leukemia; EGF, epidermal growth fac-
tor; ES, embryonic stem; KL, kit ligand; MAPK, mitogen-activated pro-
tein kinase; PDGF, platelet-derived growth factor; PEF, primary embry-
onic fibroblast.
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dok
 
cells (5). It contains a pleckstrin homology (PH) domain in
the N-terminal region, followed by a phosphotyrosine
binding (PTB) domain also called DKH (Dok homology
region, see below), as well as 15 tyrosines and 10 PXXP
motifs, most of which are at the COOH-terminal of the
protein. Characterization of p62
 
dok
 
 revealed its identity to
the long-sought RasGAP-associated 62-kD protein which
was observed being rapidly phosphorylated in various cells
upon activation of many receptors, such as platelet-derived
growth factor receptor (PDGFR) (6), epidermal growth
factor receptor (EGFR) (7), insulin receptor (8), CSF-1R
(9), kit (10), IL-3R and IL-4R (11), B cell receptor (12),
Fc
 

 
RIIB receptor (13), and CD28 (14), and nonreceptor,
cytoplasmic kinases such as Tec (15). Furthermore, the
phosphorylation status of p62
 
dok
 
 was found to be constitu-
tively elevated in v-Src–, v-Fms–, and v-Fps–transformed
cells (7, 16). Once phosphorylated, p62
 
dok
 
 interacts, through
its Src homology 2 (SH2)-binding sites, with a number of
signaling molecules such as RasGAP (7), Nck (17), and Csk
(13), thus likely placing itself at the crossroads of several
signal transduction pathways. The association with Ras-
GAP is particularly intriguing, as p62
 
dok
 
 might regulate Ras
activity by affecting, for example, the localization and/or
the function of GAP.
It has recently become evident that p62
 
dok
 
 is a prototype
member of a new docking protein family characterized by
the presence of a PH domain, a DKH region, and several
tyrosine sites and PXXP motifs (18). The additional mem-
bers of this “dok” (downstream of tyrosine kinases) family
include p56
 
dok-2
 
 (18) (also called IL-4R interacting protein
[FRIP; reference 11] or Dok-R [19]), and dok-3 or DOKL
(18, 20, 21). Notably, p56
 
dok-2
 
 shares most structural fea-
tures and the same pattern of expression with p62
 
dok
 
, with
the exception of B cells, where p56
 
dok-2
 
 is not expressed,
thus raising the possibility that these two dok members
might exert similar functions.
Given that p62
 
dok
 
 can be phosphorylated upon activation
of various kinases, it is likely to play an important role in
multiple signaling events. Yet, the exact function of p62
 
dok
 
in these events remains unclear. Recently, it has been re-
ported that, in B cells, p62
 
dok
 
 negatively regulates mitogen-
activated protein kinase (MAPK) activation and cell prolif-
eration upon coaggregation of B cell receptor and Fc
 

 
RIIB
(22, 23). However, it remains to be shown whether p62
 
dok
 
serves a similar role in other cell types and/or upon activa-
tion of different receptors or kinases. In fact, studies by
Kashige et al
 
.
 
 showed that binding of p62
 
dok
 
, phosphory-
lated by p210
 
bcr-abl
 
, to RasGAP resulted in Ras activation in
an in vitro
 
 
 
biochemistry assay (24), and they suggested that
the p210
 
bcr-abl
 
 might lead to the activation of Ras through
p62
 
dok
 
 phosphorylation. To address the above issue, as well
as to analyze the biological function of p62
 
dok
 
 in a broader
context and to determine its relevance as a p210
 
bcr-abl
 
 sub-
strate in CML pathogenesis, we have inactivated 
 
p62
 
dok
 
 
 
by
homologous recombination. Comparing cells derived from
 
p62
 
dok
 

 
/
 

 
 and wild-type mice, we show that p62
 
dok
 
 is a
negative regulator of growth factor–induced cell prolifera-
tion in several cell types including mast cells, thymocytes,
 
bone marrow cells, as well as nonhemopoietic primary
mouse embryo fibroblasts. We also found that 
 
p62
 
dok
 
 inacti-
vation resulted in sustained activation of Ras and MAPK in
primary mast cells and primary embryonic fibroblasts
(PEFs) after the removal of growth factor. Nonetheless, the
loss of p62
 
do
 
k
 
 did not affect DNA damage or growth factor
deprivation–induced apoptosis. Furthermore, the trans-
forming ability of p210
 
bcr-abl
 
 is not impaired in 
 
p62
 
dok
 

 
/
 

 
bone marrow cells and, on the contrary, p210
 
bcr-abl
 
 causes a
fatal myeloproliferative disease with shorter latency in the
absence of p62
 
dok
 
. These findings support the notion that
dok family members act as negative regulators of cell prolif-
eration and oncogenesis.
 
Materials and Methods
 
Generation and Identification of Mutant Mice.
 
A 129/Sv mouse
genomic library (Stratagene) was screened with a human 
 
p62
 
dok
 
cDNA probe. Exon/intron boundaries were determined by re-
striction enzyme mapping, DNA sequencing, and PCR. To gen-
erate the targeting construct, a 2.7-kb HindIII fragment contain-
ing 5
 

 
 
 
p62
 
dok
 
 genomic DNA and a 6.9-kb EcoRI-HindII
fragment containing 3
 

 
 sequence were cloned into pPNT (25).
The targeting construct was linearized with NotI and electropo-
rated into CJ7 embryonic stem (ES) cells. Transfectants were se-
lected in G418 (350 
 

 
g/ml) and ganciclovir (2 
 

 
M) and ex-
panded for Southern blot analysis using 5
 

 
 and 3
 
 
 
external probes
(see Fig. 1, A–C). Five correctly recombined clones were ob-
tained screening a total of 120 clones. Chimeric mice were gen-
erated by microinjection of two independently generated, tar-
geted ES cell clones with normal karyotypes into E3.5 C57BL6/J
blastocysts then transferred to pseudopregnant foster mothers.
Chimeric males were mated with C57BL6/J females (The Jack-
son Laboratory) and germ-line transmission of the mutated allele
was verified by Southern blot of tail DNA from agouti coat col-
ored F1 offspring. Chimeras were then mated to 129/Sv females
to obtain 
 
p62
 
dok
 
 mutants in the 129/Sv pure background.
 
Antibodies for Western Blot.
 
Anti-p62
 
dok
 
 monoclonal anti-
body (A-3) was purchased from Santa Cruz Biotechnology, Inc.
Anti-actin monoclonal antibody (AC-40) was purchased from
Sigma-Aldrich. Phospho-specific antibodies against p44/p42
MAPK (Thr202/Tyr204) and anti-p44/p42 MAPK antibody
were from New England Biolabs, Inc.
 
Preparation of Bone Marrow–derived Mast Cells and In Vitro Cul-
tures.
 
Primary cultures of IL-3–dependent bone marrow–
derived mast cells (BMMCs) were prepared from 6-wk-old wild-
type or 
 
p62
 
dok
 

 
/
 

 
 mice and maintained as described previously
with minor modifications (26). In brief, the mice were killed and
the bone marrow was flushed aseptically from femurs and tibias
into RPMI 1640 containing 10% heat-inactivated FCS, 50 
 

 
M
 

 
-mercaptoethanol, 2 mM 
 
l
 
-glutamine, 0.1 mM nonessential
amino acids, antibiotics (RPMI complete), and 2.5 ng/ml recom-
binant murine IL-3 (PeproTech). The nonadherent bone mar-
row cells were maintained at 37
 

 
C. Cells were fed with fresh me-
dium every 4 d. After 4 wk of culture, 
 
	
 
98% of the cells
obtained are BMMCs, as demonstrated by morphological and
flow cytometric analysis. For in vitro proliferation assays, BMMCs
in RPMI complete medium were starved of IL-3 for 12 h; 10
 
5
 
cells were seeded, in triplicate, in 96-well plates, and stimulated
with kit ligand (KL) or IL-3 for 24 h. After 20 h, 1 
 

 
Ci/well of
[
 
3
 
H]thymidine was added for 4 h. Cells were harvested and [
 
3
 
H]
radioactivity was measured.
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Apoptosis Assays.
 
8 
 


 
 10
 
6
 
 BMMCs were seeded in 4 ml
RPMI with 5% FCS without IL-3 or with 2.5 ng/ml IL-3. Cells
were harvested after 24, 48, 72 h of incubation at 37
 

 
C, stained
with annexin V as per manufacturers’ protocol, and the percent-
age of apoptotic cells was determined by FACS
 
®
 
 analysis. For in
vivo assays, 6–8-wk-old wild-type and 
 
p62
 
dok
 

 
/
 

 
 mice were
gamma irradiated with a 10 Gy dose and killed after 6 h. The per-
centage of apoptotic cells in the thymus and bone marrow was
determined by FACS
 
®
 
 analysis as described above.
 
Primary Thymocytes and Mouse Embryo Fibroblast Proliferation
Assays.
 
Thymuses from 5–8-wk-old mice were mechanically
dissociated by passing through nylon meshes. Contaminating
erythrocytes were removed by hypotonic lysis. 2 
 


 
 10
 
5
 
 cells were
cultured in 96-well plates in 100 
 

 
l of RPMI 1640 supplemented
with 2 mM glutamine, 50 M -mercaptoethanol, antibiotics,
and 10% FCS. Cells were stimulated by the addition of different
concentrations of ConA (Sigma-Aldrich) and/or recombinant
mouse IL-2 (Boehringer). For stimulation with plate-bound anti-
CD3 antibody (BD PharMingen), plates were coated overnight
at 4C with 10 g/ml of antibody in PBS, then washed twice
with PBS/1% BSA. After 32 h, 1 Ci/well of [3H]thymidine
(Amersham Pharmacia Biotech) was added and the cells were har-
vested 16 h later for [3H]thymidine incorporation determination.
Mouse embryo fibroblasts (MEFs) were harvested from 13.5-
d-old embryos and cultured in DMEM supplemented with 2 mM
glutamine, 50 M -mercaptoethanol, antibiotics, and 10% FCS.
For proliferation analysis, cells were plated (5 
 104/well) in 96-
well plates, serum starved in 0.5% FCS for 24 h, and then stimu-
lated by the addition of 50 ng/ml PDGF (Sigma-Aldrich). After
12 h, 1 Ci/well of [3H]thymidine was added and the cells were
harvested 3 h later for [3H]thymidine incorporation.
In Vitro Bone Marrow Cultures. For liquid cultures, bone mar-
row from 8–16-wk-old mice was obtained by flushing the femurs
with IMDM. Contaminating erythrocytes were removed by hy-
potonic lysis. Live cells were counted and plated (106/ml) in
RPMI 1640 supplemented with 2 mM glutamine, 50 M -mer-
captoethanol, antibiotics, 200 g/ml transferrin (Sigma-Aldrich),
10 g/ml insulin (Boehringer), 1% BSA, and 10 ng/ml IL-3
(R&D Systems). Live cells were counted at the indicated time-
points by trypan blue exclusion. For cultures in methylcellulose,
bone marrow cells were plated in MethoCult GF M3434 (Stem-
Cell Technologies Inc.).
MAPK Analysis. PEFs were serum starved in 0.5% FCS for
24 h, and then stimulated for 10 min with 50 ng/ml PDGF, 100
ng/ml EGF (Sigma-Aldrich), or 10 g/ml insulin (Boehringer).
BMMCs were serum starved in RPMI plus 1% FCS for 6 h, and
then stimulated for 5 min with 2.5 ng/ml IL-3. At the end of the
stimulation, cells were immediately washed with PBS and replated
in serum-free medium. At different time points, the cells were
washed with ice-cold PBS containing 1 mM sodium vanadate
(Na3VO4), and lysed in 1 ml ice-cold lysis buffer consisting of 1%
Triton X-100, 0.5% NP-40, 150 mM NaCl, 10 mM Tris HCl,
pH 7.4, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 10 mM
NaF, 1 mM -glycerophosphate, 25 mM sodium pyrophosphate,
and protease inhibitor cocktail (Roche). Cell debris was pelleted,
and supernatants containing the whole cell lysates were analyzed
on SDS-polyacrylamide gels. Proteins were transferred to nitrocel-
lulose membranes and immunoblotted with phospho-specific
p44/p42 MAPK antibody to reveal the presence of activated
MAPK. To verify equivalent loading and to confirm the identity
of the phosphorylated MAPK, membranes were stripped with 100
mM -mercaptoethanol, 2% SDS, 62.5 mM Tris (pH 6.7) at 55C
for 30 min and blotted with p44/p42 MAPK antibody. Immuno-
blots were visualized with enhanced chemiluminescence detection
reagents (ECL; Amersham Pharmacia Biotech).
Ras GTP/GDP Binding Analysis. Wild-type and p62dok/
PEF cells were labeled for 18 h with [32P] Pi (Amersham Pharma-
cia Biotech) at 0.25 mCi/ml in phosphate-free and serum-free
DMEM (Gibco-BRL). The cells were treated with PDGF at 50
ng/ml for 10 min, then twice washed with phosphate-free and
serum-free medium and incubated in the same medium for an
additional 15 and 30 min. After treatment, the cells were washed
twice with ice-cold PBS and lysed in lysis buffer (50 mM Tris-
HCl, pH 7.5, 20 mM MgCl2, 150 mM NaCl, 0.5% NP-40, 10
g/ml aprotinin, 1 mM PMSF) including 4 g/ml anti–v-H-ras
monoclonal antibody (Y13-259; Oncogene Research Products).
The cells were scraped off, and harvested by centrifugation. To
the supernatants of each sample, 0.1 ml 10% activated charcoal
was added. The mixtures were incubated for 1 h and the charcoal
was removed by centrifugation. 2 l of each sample was taken to
measure the counts of the samples. Equal counts were taken for
each sample and they were then adjusted to the same volume by
adding lysis buffer and incubated with 60 l protein A-Sepharose
CL-4B (Amersham Pharmacia Biotech) precoupled with rabbit
anti–rat IgG (ICN Biomedicals) for 1.5 h. The beads were pre-
cipitated by centrifugation, washed twice with lysis buffer and
once with ice-cold PBS, and the nucleotides were eluted with 75
mM KH2PO4, pH 3.4, 5 mM EDTA, 2 mM DTT, 0.5 mM
GTP, and 0.5 mM GDP at 85C for 3 min. Separation of eluted
nucleotides was on a polyethyleneimine cellulose plate in 0.65 M
KH2PO4 (pH 3.4). The amount of radioactivity present in the
GDP and GTP was quantitated with a PhosphorImager (BAS
2000; Fuji Photo Film Co.). The results represented are an aver-
age from three independent experiments.
Bone Marrow Infection and Transplantation Experiments. Trans-
fection of the retroviral construct Mig210, bone marrow isolation
from 12-wk-old wild-type and p62dok/ mice (in the 129/Sv
pure genetic background), prestimulation and infection, and
transplantation into lethally irradiated 129/Sv mice were per-
formed essentially as follows (see also reference 27): wild-type and
p62dok/ mice were injected with 5 mg of 5-fluorouracil (5-FU).
4 d later, mice were killed, bone marrow cells isolated and sub-
jected to prestimulation in DMEM with 15% FCS, 5% WEHI-3
conditioned medium, 6 ng/ml rmIL-3, 10 ng/ml rmIL-6, and
100 ng/ml rmSCF for 24 h. IL-3, IL-6, and SCF were purchased
from PeproTech. After prestimulation, bone marrow cells were
infected with the retroviral supernatant in DMEM with 15%
FCS, 5% WEHI-3 conditioned medium, 6 ng/ml IL-3, 10 ng/ml
IL-6, 100 ng/ml SCF, and 2 g/ml Polybrene by spin infection
using Sorvall RT6000D with 1,000 g for 90 min at 37C. To de-
termine whether inactivation of p62dok affects response to 5-FU
and/or prestimulation, bone marrow cells were analyzed before
and after prestimulation: (a) by FACS® analysis using combina-
tions of anti–c-kit-PE, anti–CD34-FITC and anti–Mac-1-PE,
anti–Gr-1-FITC antibodies; (b) by performing in vitro colony as-
say in MethoCult GF M3434 (StemCell Technologies Inc.). Col-
ony number was counted on day 7 and 12. No differences were
found between the two genotypes. After spin infection and 24 h
culture in CO2 incubator, cells were counted and washed twice
in PBS. 5 
 105 cells were injected into the tail vein of irradiated
(9.5 Gy as single dose) 129/Sv recipient mice. Infected bone mar-
row cells were in parallel subjected to FACS® analysis to measure
GFP expression and in turn levels of infection by the retrovirus.
GFP expression levels in wild-type and p62dok/ mice derived
bone marrow cells were indistinguishable, thus demonstrating
that p62dok inactivation does not affect retroviral infection effi-
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ciency. Upon transplantation, total and differential counts were
performed on peripheral blood cells of recipient mice every 5 d.
Cells obtained from peripheral blood and bone marrow of dis-
eased leukemic animals were also analyzed for expression of GFP
and Gr-1 markers. Antibodies for FACS® analysis were purchased
from BD PharMingen.
Results
Generation of p62dok/ Mice. To create a p62dok null al-
lele via homologous recombination in mouse ES cells, we
isolated genomic clones of the murine p62dok locus screen-
ing an isogenic 129/Sv mouse genomic library with a hu-
man p62dok cDNA probe. Two overlapping clones were
obtained which spanned the p62dok locus. A positive/nega-
tive targeting vector, containing 2.7 kb of 5 and 6.9 kb of
3 genomic homology in the PNT vector (25), was de-
signed to replace the coding region from exon 1 to part of
exon 5 with the neomycin-resistance gene (Neo) cassette
(Fig. 1 A). Five mutant CJ7 ES clones heterozygous for the
p62dok mutation were generated as described in Materials
and Methods section (Fig. 1 B). Two clones, euploid at the
karyological analysis, were expanded for injection of
C57BL/6 blastocysts. Both clones gave rise to highly chi-
meric mice that were then mated with C57BL/6 females to
obtain germ line transmission of the mutant alleles. Chime-
ras from both clones transmitted the mutation to the germ
line and were subsequently mated to 129/Sv females to ob-
tain p62dok heterozygotes (/) in a pure genetic back-
ground. p62dok/ mice were intercrossed and genotypes
were determined by Southern blot (Fig. 1 C). From these
crosses, p62dok/ mice were born following Mendelian
frequencies. p62dok/ mice did not display overt develop-
mental defects and were fertile. Functional disruption of
the p62dok gene was confirmed by Western blot analysis of
protein extracts from spleen and thymus (Fig. 1 D).
p62dok Controls Cell Proliferation upon Mitogenic Stimuli.
Total and differential peripheral blood counts, flow cyto-
metric analysis of peripheral blood, thymus, spleen, and
bone marrow, as well as in vitro bone marrow culture un-
der standard conditions (i.e., growth of total marrow in
methylcellulose in the presence of hematopoietic growth
factors: Materials and Methods) demonstrated that inactiva-
tion of p62dok does not affect hematopoiesis in the mouse at
the steady state (data not shown).
To determine the effect of p62dok inactivation in the ab-
sence of physiological compensatory mechanisms, we ana-
lyzed the growth response of wild-type and p62dok/ he-
mopoietic and fibroblast cells to mitogenic stimuli. As
p62dok is phosphorylated in response to c-kit and IL-3 re-
ceptor engagement, we employed BMMCs as a model cell
system. BMMCs are a unique model system to study the
effects of these cytokines on cell proliferation and apoptosis
in a homogeneous population. In fact, although primary
totipotent hemopoietic stem cells can not be maintained in
long-term cultures, primary BMMCs can be propagated in
Figure 1. Targeted disruption
of the p62dok gene. (A) Structure
of the p62dok gene (top), the tar-
geting construct (center), and the
predicted structure of the dis-
rupted p62dok gene after homolo-
gous recombination (bottom).
Only the relevant restriction sites
are shown: B, BamH1; H2,
HindII; R, EcoR1; H3, HindIII.
The numbered solid boxes rep-
resent the exons. Neo and TK
(herpes simplex virus thymidine
kinase) refer to the positive and
negative selection markers, re-
spectively. The genomic frag-
ments used as probes for South-
ern blot analysis are indicated, as
well as the expected fragments
after hybridization with the two
probes, upon digestion with
BamH1 and HindIII. (B) South-
ern blot analysis of ES cells
clones after digestion with Hind
III and hybridization with the 3
external probe. (C) Southern
blot analysis of BamH1-digested
genomic DNA from F2 mice re-
sulting from a cross between two
p62dok/ mice. The blot was
hybridized with the 5 probe.
(D) Western blot analysis of thy-
mus and spleen from wild-type
and p62dok/ mice, showing the
absence of p62dok.
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Figure 2. Effect of p62dok disruption on BMMCs
proliferation. (A) Morphology of wild-type (wt)
and p62dok/ BMMCs. (B) Expression of p62dok
and actin detected by Western blot analysis in pro-
tein extracts (60 g) from BMMCs. (C and D)
Proliferative response, determined as [3H]thymi-
dine incorporation, of wild-type and p62dok/
BMMCs upon KL and IL-3 stimulation. Wild-
type, white bar; p62dok/, black bar. All graphs are
representative of experiments repeated three to five
times. Error bars represent standard deviation.
Figure 3. Effect of p62dok disruption on cell
proliferation in thymocytes, total bone marrow
cells and PEFs. (A and B) Proliferative response,
determined as [3H]thymidine incorporation, of
wild-type and p62dok/ thymocytes upon plate-
bound CD3 and ConA (3 g/ml) stimulation,
in the presence of IL-2 (100 U/ml). Wild-type,
black bar; p62dok/, gray bar. (C) Proliferation of
wild-type and p62dok/ thymocytes upon increas-
ing concentrations of ConA and constant amount
of IL-2 (100 U/ml). Wild-type, filled square and
dashed line; p62dok/, filled circle and solid line.
(D) Phosphorylation of p62dok upon ConA stimu-
lation. (E) In vitro proliferation of wild-type and
p62dok/ bone marrow cells in serum-free me-
dium, in the presence of 10 ng/ml IL-3, measured
by manual cell counting. Wild-type, filled square
and dashed line; p62dok/, filled circle and solid
line. (F) Proliferative response, determined as
[3H]thymidine incorporation, of wild-type and
p62dok/ PEFs upon PDGF stimulation. Wild-
type, black bar; p62dok/, gray bar. All graphs are
representative of experiments repeated three to
five times. Error bars represent standard deviation.
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vitro, express both c-kit and IL-3 receptors, and responses
to IL-3 and KL in BMMCs have been well characterized
(28, 29). Morphological analysis of wild-type and p62dok/
BMMCs did not reveal differences between the two cell
populations (Fig. 2 A). Moreover, flow cytometric analysis
using anti–c-kit, anti–Sca-1, anti–Mac-1, and anti–Gr-1
antibodies showed the same expression levels of these sur-
face molecules (data not shown). Next, we tested by West-
ern blot the expression of p62dok in wild-type and p62dok/
BMMCs. p62dok protein expression was readily detectable
in wild-type BMMCs but not in p62dok/ cells (Fig. 2 B).
The mitogenic effects of KL and IL-3 were characterized
by determining the dose-response relationship for KL and
IL-3–induced DNA synthesis. Inactivation of p62dok consis-
tently resulted in increased incorporation rates of [3H]thy-
midine upon treatment of starved BMMCs with low con-
centrations of these cytokines (Fig. 2, C and D). Thus,
p62dok negatively modulates the mitogenic effect of KL and
IL-3 in bone marrow mast cells.
To investigate whether the effect of p62dok disruption on
mitogenic signals is common to other hemopoietic cell
populations, we performed similar assays on thymocytes
purified from wild-type and p62dok/ mice. Thymocytes,
maintained in IL-2, were activated with ConA or with
plate-bound anti-CD3 antibody and [3H]thymidine in-
corporation was subsequently determined. No significant
difference was found between wild-type and p62dok/ thy-
mocytes stimulated with anti-CD3 (Fig. 3 A), in agree-
ment with the notion that p62dok is not phosphorylated
upon CD3 engagement (30). On the contrary, ConA stim-
ulation resulted in a marked increase in [3H]thymidine up-
take in the p62dok/ cells (Fig. 3 B). To ensure that this ef-
fect was due to an enhanced sensitivity to ConA, we
measured [3H]thymidine incorporation using constant con-
centration of IL-2 and increasing concentrations of ConA.
p62dok/ cells were hyperresponsive to ConA stimulation
in a dose-dependent manner (Fig. 3 C). In contrast, keep-
ing the ConA concentration constant, wild-type and
p62dok/ cells responded to IL-2 in a comparable manner
(data not shown). To further assess the involvement of
p62dok in the effect triggered by ConA, we compared the
phosphorylation status of p62dok in freshly isolated thy-
mocytes and in cells stimulated with ConA for 24 h. As
shown in Fig. 3 D, culture of the cells in the presence of
ConA resulted in the phosphorylation of p62dok. Thus, in
thymocytes, ConA induces p62dok phosphorylation, which
in turn negatively regulates ConA-induced proliferation.
We next analyzed the response of primary bone marrow
cells derived from wild-type and p62dok/ mice to IL-3,
which is a known hemopoietic growth factor. Freshly iso-
lated bone marrow cells were cultured in serum-free me-
dium in the presence of IL-3. p62dok/ cells showed an in-
creased expansion in response to IL-3 (Fig. 3 E).
To determine whether the aberrant proliferative re-
sponse observed in p62dok/ thymocytes and bone marrow
cells is shared by nonhemopoietic cell types, we examined
the growth properties of wild-type and p62dok/ PEFs in
response to PDGF. Upon PDGF stimulation, p62dok/
PEFs showed increased levels of [3H]thymidine incorpora-
tion compared with wild-type cells (Fig. 3 F). Similar data
were obtained for insulin and EGF (data not shown). Thus,
p62dok negatively regulates proliferative response to mito-
genic stimuli in cells from various histological origins.
p62dok Inactivation Does Not Affect Growth Factor Depriva-
tion and DNA Damage–induced Apoptosis. p210bcr-abl pro-
tects hemopoietic cells from apoptotic stimuli such as DNA
damage and growth factor withdrawal (31, 32). It is there-
fore conceivable, at least in principle, that the phosphoryla-
tion of p62dok by p210bcr-abl might affect the survival signals
generated by the oncoprotein. We therefore determined
the effect of p62dok loss on growth factor deprivation–induced
apoptosis. To this end, actively proliferating BMMCs were
deprived of IL-3 and analyzed at different time points by
annexin V staining. p62dok/ BMMCs underwent apop-
tosis with the same kinetics and extent as their wild-type
counterpart (Fig. 4 A). We next irradiated wild-type and
p62dok/ mice (n  4 and 4) with a 10 Gy dose and exam-
ined the apoptotic response of thymocytes and bone mar-
row cells 6 h after irradiation. No differences were detect-
able between wild-type and p62dok/ mice (Fig. 4 B).
Thus, disruption of p62dok does not affect the apoptotic re-
sponse to growth factor deprivation and DNA damage in
hemopoietic cells.
Sustained Ras and MAPK Activation in p62dok/ Cells.
To define the molecular basis of the increased proliferative
response of p62dok/ cells, we analyzed the kinetics and
extent of MAPK activation upon PDGF stimulation of
PEFs. Wild-type and p62dok/ PEFs were serum starved
for 24 h and then treated for 10 min with growth factors.
Cells were subsequently washed with PBS and serum-free
medium was added. Total protein extracts were prepared
from unstimulated cells, growth factor–stimulated cells, as
well as 15, 30, and 60 min after removal of growth factors
Figure 4. Effect of p62dok disruption on growth factor deprivation and
DNA damage–induced apoptosis. (A) Kinetics of the apoptotic response
to IL-3 deprivation in BMMCs. Cell death was analyzed by annexin V
staining of wild-type (filled square) and p62dok/ (filled circle) cells at the
indicated time points after IL-3 withdrawal (solid lines) or in the presence
of IL-3 as a control (dashed lines). (B) In vivo apoptotic response to irra-
diation. Mice were irradiated (10 Gy) and killed after 6 h. Cell death was
analyzed by annexin V staining of bone marrow cells (BM) and thy-
mocytes (Thy). The percent of spontaneous apoptosis in unirradiated lit-
termates has been subtracted from the values shown in the graph. Wild-
type, black bar; p62dok/, gray bar.
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to examine the duration of MAPK activation. p62dok was
readily phosphorylated in wild-type cells (Fig. 5 A). The
analysis of MAPK activation clearly demonstrate that al-
though the level of ERK 1/2 phosphorylation before and
during growth factor treatment is comparable in p62dok/
and wild-type cells, ERK 1/2 phosphorylation upon
growth factor withdrawal is considerably prolonged in
p62dok/ cells (Fig. 5, A and B). Similar data were obtained
using insulin and EGF (data not shown). Rescue experi-
ments in which retroviral-mediated reintroduction of
p62dok into p62dok/ PEFs reversed the increased cell pro-
liferation and the prolonged MAPK activity observed in
these cells, proved the specificity of such phenotype (see
accompanying paper by Zhao et al.). Therefore, p62dok ap-
pears to downregulate the duration of MAPK activity upon
growth factor stimulation.
To examine whether the effect of p62dok on MAPK ac-
tivity occurs through Ras, we labeled the cells and treated
them as described above. Cell lysates were subjected to im-
munoprecipitation with an anti-p21ras antibody. Guanine
nucleotides bound to the p21ras immunoprecipitates were
separated by TLC and quantified as shown in Fig. 5 C. The
basal level of Ras activity was slightly higher in p62dok/
when compared with wild-type cells. Furthermore, similar
as seen for MAPK activity, the amount of Ras-GTP in
p62dok/ remained significantly higher after removal of
PDGF when compared with wild-type cells, suggesting
that p62dok negatively influences Ras signaling.
To determine whether prolonged MAPK activation as a
result of p62dok inactivation is common to different cell
types, and whether this mechanism can be responsible for
the increased DNA synthesis rates observed, we analyzed
the duration of MAPK activation upon IL-3 stimulation of
BMMCs. Once again, removal of IL-3 resulted in a prompt
downregulation of MAPK phosphorylation in wild-type
cells, whereas the levels of phospho-ERK 1/2 decreased
with a slower kinetics in p62dok/ cells (Fig. 5, D and E).
p62dok Inactivation Results in Acceleration of Leukemogenesis
by p210bcr-abl. As p62dok is a major phosphorylation sub-
strate of the p210bcr-abl oncoprotein in CML cells (4), it is
Figure 5. p62dok controls MAPK and ras activation. (A and B) Phosphorylation
of p62dok (indicated by an asterisk) and ERK1/2 in response to PDGF. PEF were
serum starved and then stimulated with 50 ng/ml PDGF for 10 min. Then, the cells
were washed and serum-free medium was added to analyze the kinetics of ERK in-
activation. The amount of cell extracts was normalized using an antibody recogniz-
ing ERK1/2 independently of its phosphorylation status. Normalized densitometric
analysis of ERK1/2 phosphorylation is shown in B. (C) Ras GTP/GDP binding
analysis. Wild-type and p62dok/ PEFs were serum starved, labeled with 32Pi for
18 h, and treated with 50 ng/ml PDGF for 10 min. Then the cells were washed
twice and incubated in phosphate-free and serum-free medium for additional 15
and 30 min. Cells at different indicated time points were lysed, ras was immunopre-
cipitated, and the GTP and GDP present in the immunoprecipitates were resolved
on a thin-layer polyethyleneimine-cellulose plate. The radioactivity in the GTP and
GDP was quantitated with a Fuji Photo Film Co., BAS2000 PhosphorImager. The
data are expressed as percent GTP, which was calculated by valueGTP /(1.5 
 valueGDP  valueGTP) 
 100. Wild-type, filled circle and dashed line;
p62dok/, filled diamond and solid line (D and E). Phosphorylation of ERK1/2 in BMMCs in response to IL-3. BMMCs were serum starved and then
stimulated with 2.5 ng/ml IL-3 for 5 min. Then, the cells were washed and serum-free medium was added to analyze the kinetics of ERK inactivation.
The amount of cell extracts was normalized using an antibody recognizing ERK1/2 independently of its phosphorylation status. Normalized densitomet-
ric analysis of ERK1/2 phosphorylation is shown in E. All graphs are representative examples of experiments repeated three to five times.
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possible that it plays an essential role in p210bcr-abl-mediated
transformation. To address this point, bone marrow cells
from wild-type and p62dok/ mice in the 129/Sv genetic
background were infected with retroviral constructs coex-
pressing the GFP marker and the p210bcr-abl oncoprotein
following a protocol schematically summarized in Fig. 6 A
and described in detail in Materials and Methods.
Wild-type and p62dok/ transduced cells were trans-
planted into lethally irradiated 129/Sv mice and total and
differential peripheral blood counts were performed every
5 d. Mice transplanted with wild-type–derived bone mar-
row developed elevated blood counts after day 18 and died
between day 21 and day 27 (Fig. 6 B). In mice transplanted
with infected bone marrow cells derived from p62dok/
mice we observed a marked and significant acceleration of
leukemia onset (P  0.0018; Fig. 6 B). In the p62dok/ co-
hort, high blood counts (between 120 and 240 
 103/l)
were observed by day 10, and mice succumbed between
day 11 and day 18 (Fig. 6 B). Postmortem pathological
analysis in these animals consistently showed in both co-
horts hepatosplenomegaly with organs infiltrated by both
immature myeloid progenitors and mature granulocytes
(not shown). Flow cytometric analysis demonstrated that
about 50% of myeloid cells were, as expected, infected
with the p210bcr-abl expressing retrovirus (GFP-positive
cells) in both genotypes (Fig. 6 C). Flow cytometric and
morphological analyses of peripheral blood and bone mar-
row leukocytes confirmed the myeloid nature of the dis-
ease and that the hematological features of the disease in
the two groups were indistinguishable (Fig. 6 C, and not
shown). Thus, the absence of p62dok does not prevent the
ability of p210bcr-abl to transform hemopoietic progenitors,
but rather results in the acceleration of the onset of the
CML-like disease triggered by p210bcr-abl.
Discussion
Phosphorylation of p62dok has been observed after acti-
vation of receptor and nonreceptor tyrosine kinases, as well
as in relation to oncogenic transformation (6–16). Once
phosphorylated, it associates to RasGAP among other sig-
naling molecules, thus leading to the assumption that
p62dok might positively regulate cell cycle progression
through enhancing Ras signaling pathway. This notion was
further corroborated by a recent report, in which in vitro
studies showed that binding of p210bcr-abl-phosphorylated
p62dok to RasGAP resulted in Ras activation (24). How-
ever, in vivo studies have showed opposite results and sup-
port a model in which p62dok plays a negative role in prolif-
eration induced by coaggregation of B cell receptor and
FcRIIB (22). Our studies confirm and further extend this
model, showing that p62dok negatively regulates growth
factor–induced cell proliferation, at least in part by nega-
tively regulating Ras and MAPK pathway, as well as
p210bcr-abl-induced cellular transformation.
p62dok Is a Negative Regulator of Cell Proliferation and Ras
and MAPK Activation. We found that, although p62dok/
mice are healthy and fertile, null cells of various histological
Figure 6. Retroviral transduction of
p210bcr-abl results in the transformation
of p62dok/ bone marrow cells. (A)
Schematic representation of the proto-
col for retroviral transduction of bone
marrow and subsequent reconstitution
into lethally irradiated recipients (refer-
ence 27). (B) Survival of 129/Sv wild-
type mice receiving transduced bone
marrow cells derived from wild-type
(filled square and dashed line) and
p62dok/ (filled circle and solid line)
mice. Log rank statistical analysis was
performed to obtain P. (C) Flow cyto-
metric analysis of peripheral blood (top),
and bone marrow cells (bottom), from a
mouse transplanted with p210bcr-abl
transduced p62dok/ bone marrow cells,
using a granulocyte surface marker (Gr-
1). In the peripheral blood, almost all
the infected cells (cells expressing GFP)
coexpress the myeloid-specific marker.
In the bone marrow, 50% of the cells
express GFP and 	60% of these are Gr-1
positive. A similar immunophenotypi-
cal pattern was observed in mice trans-
planted with wild-type–derived bone
marrow (not shown).
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origins proliferate faster than wild-type cells in response to
growth factor/cytokine stimulation. Furthermore, we ob-
served sustained MAPK activation and prolonged levels of
activated (GTP-bound) Ras after growth factor removal.
Importantly, our results expand the notion that p62dok is
not only a negative regulator of antigen receptor signaling
of B cells, but also of signaling events initiated by growth
factor receptors in cells of various histological origin in-
cluding bone marrow cells, which are target of the leuke-
mogenic potential of p210bcr-abl. Furthermore, our data in-
dicate that p62dok may do so, at least in part, by negatively
influencing Ras and MAPK activity.
Current studies on other members of the Dok family il-
lustrated consistent results. It was shown that overexpres-
sion of p56dok-2 downregulated MAPK activity in response
to EGF in Cos-1 cells (33), as well as upon IL-2 stimulation
in IL-2R transfected 32D cells (11). Moreover, ectopic
expression of dok-3 has been shown to suppress v-Abl–
induced MAPK activation and to negatively regulate B cell
receptor initiated signaling events, however, independent
of MAPK activity (20, 21). Taken together, these observa-
tions suggest that the Dok family members negatively in-
fluence common as well as distinct physiological signaling
events.
Based on the above, it is not so surprising that the inacti-
vation of p62dok does not lead to an overt phenotype in the
mice at the steady state. It is possible that other members of
the dok family can compensate for the absence of p62dok,
especially p56dok-2, which has previously been shown to be
very similar to p62dok at the amino acid level and coex-
pressed with p62dok in most tissues (18). Simultaneous inac-
tivation of two or multiple genes of the Dok family mem-
bers in the mouse will provide us more insight on their
functional characterization.
A Negative Role of p62dok in Leukemogenesis by p210bcr-abl.
The identification and characterization of specific targets of
p210bcr-abl aberrant tyrosine kinase activity might uncover
the molecular basis underlying the pathogenesis of the
chronic phase of CML. Although p62dok was initially
thought to be a possible mediator of p210bcr-abl transform-
ing activity due to its high phosphorylation in CML blasts,
its negative role in growth factor signaling events implied
that the phosphorylation of p62dok is not required for, even
conversely, may oppose the leukemogenic process by
p210bcr-abl. Indeed, our results showed that the absence of
p62dok did not reduce the ability of p210bcr-abl to transform
the corresponding early hemopoietic progenitors. In fact,
mice reconstituted with p62dok/ bone marrow cells in-
fected with a p210bcr-abl retrovirus succumbed with a
shorter latency than the controls. Thus, our data indicate
that p62dok opposes leukemogenesis by p210bcr-abl. Consis-
tent with the above, Cong et al. showed that overexpres-
sion of dok-3 reduced the colony forming ability of v-abl–
transformed NIH3T3 cells (20). Moreover, Songyang et al.
recently found that overexpression of p62dok diminishes the
colony forming ability of v-src–transformed NIH3T3 cells
(34).
Given the observed negative regulatory activity of
p62dok, it is tempting to speculate that p210bcr-abl-triggered
phosphorylation of p62dok, may lead to the activation of
p62dok as a negative regulator, and as such interfering with
p210bcr-abl-induced transformation. On the other hand, we
can not exclude the possibility that phosphorylation of
p62dok triggered by p210bcr-abl leads to inactivation of
p62dok’s negative activity in normal signaling events. In the
latter case, in cells harboring the p210bcr-abl oncoprotein,
the tumor-growth suppressive activity of p62dok may be
partially abrogated. Irrespective of these possibilities, our
data conclusively demonstrate that, in vivo, p62dok is not
required for the transduction of the leukemogenic signal
and that its loss accelerates oncogenesis by p210bcr-abl. Char-
acterization of mice in which two or more Dok genes have
been inactivated will provide conclusive evidence in sup-
port of the notion that dok proteins can be regarded as
bona fide tumor suppressors.
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